股价跌破1元 *ST长药回应:不出意外将退市!

Core Viewpoint - *ST Changyao faces significant financial and legal challenges, including potential delisting due to continuous financial losses and allegations of falsifying financial reports [2][5][6]. Financial Performance - The company reported a negative net asset of -4.33 billion yuan for the fiscal year 2024, which may lead to delisting if the negative trend continues into 2025 [5]. - The audited net profits for 2022, 2023, and 2024 were -76.39 million yuan, -632 million yuan, and -569 million yuan respectively, indicating a consistent decline in financial performance [5]. Legal Issues - The company has been under investigation by the China Securities Regulatory Commission (CSRC) for inflating revenue and profits over three consecutive years, leading to a proposed fine of 10 million yuan for the company and 31 million yuan for 14 responsible individuals [6]. - A court ruling denied the company's restructuring application, citing a lack of feasibility, and declared bankruptcy for several subsidiaries [4]. Stock Market Impact - On December 30, the stock price dropped to 0.95 yuan per share, a decline of 19.49%, marking the first time the stock closed below 1 yuan, which could trigger delisting procedures [2][3]. - The stock has been placed under a delisting risk warning effective December 29, 2025, due to the ongoing financial and legal issues [5].

股价跌破1元 *ST长药回应:不出意外将退市! - Reportify